CoChat

Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression

Open access
Vecera, Courtney M., C. Courtes, Alan, Jones, Gregory, Soares, Jair C., Machado-Vieira, Rodrigo · 2023 · Pharmaceuticals

The DOI matches its Crossref record; 177 of the 179 references it cites were found in a registry or an index; 83 of the 280 sources its claims cite were checked for support.

Abstract

Treatment-resistant depression (TRD) is a term used to describe a particular type of major depressive disorder (MDD). There is no consensus about what defines TRD, with various studies describing between 1 and 4 failures of antidepressant therapies, with or without electroconvulsive therapy (ECT). That is why TRD is such a growing concern among clinicians and researchers, and it explains the necessity for investigating novel therapeutic targets beyond conventional monoamine pathways. An imbalance between two primary central nervous system (CNS) neurotransmitters, L-glutamate and γ-aminobutyric acid (GABA), has emerged as having a key role in the pathophysiology of TRD. In this review, we provide an evaluation and comprehensive review of investigational antidepressants targeting these two systems, accessing their levels of available evidence, mechanisms of action, and safety profiles. N-methyl-D-aspartate (NMDA) receptor antagonism has shown the most promise amongst the glutamatergic targets, with ketamine and esketamine (Spravato) robustly generating responses across trials. Two specific NMDA-glycine site modulators, D-cycloserine (DCS) and apimostinel, have also generated promising initial safety and efficacy profiles, warranting further investigation. Combination dextromethorphan-bupropion (AXS-05/Auvelity) displays a unique mechanism of action and demonstrated positive results in particular applicability in subpopulations with cognitive dysfunction. Currently, the most promising GABA modulators appear to be synthetic neurosteroid analogs with positive GABAA receptor modulation (such as brexanolone). Overall, advances in the last decade provide exciting perspectives for those who do not improve with conventional therapies. Of the compounds reviewed here, three are approved by the Food and Drug Administration (FDA): esketamine (Spravato) for TRD, Auvelity (dextromethorphan-bupropion) for major depressive disorder (MDD), and brexanolone (Zulresso) for post-partum depression (PPD). Notably, some concerns have arisen with esketamine and brexanolone, which will be detailed in this study.

Overview

CoChat Summary

TL;DR

This review evaluates investigational pharmacotherapies targeting glutamate–GABA neurotransmission for treatment-resistant depression (TRD), concluding that NMDA receptor antagonism—especially ketamine and esketamine—has the strongest evidence, while synthetic neurosteroid GABA-A modulators are the most promising GABAergic agents. Three reviewed compounds are FDA-approved: esketamine for TRD, dextromethorphan–bupropion (Auvelity) for MDD, and brexanolone for postpartum depression.

Key findings

  • TRD lacks a consensus definition; the modal definition is lack of response or remission after two adequate antidepressant trials, but only 17% of studies implement these criteria, and approximately one-third of depressed patients fail to remit even after four adequate therapeutic trials.
  • Ketamine has robust evidence: a single dose can alleviate depressive symptoms for up to seven days with effects peaking at 24 h, and repeated infusions maintain effects for two to three weeks in MDD; a meta-analysis favored intravenous ketamine over intranasal esketamine for response (RR = 3.01 vs. 1.38), remission (RR = 3.70 vs. 1.47), and lower dropouts (RR = 0.76 vs. 1.37).
  • Esketamine nasal spray was approved in 2019 for TRD after five phase III randomized double-blind placebo-controlled trials and one open-label trial; a long-term open-label study reported sustained improvement at 2 years, with 0.6% discontinuing for worsening depression and 0.2% for suicidal ideation, though one successful suicide occurred.
  • Among GABA modulators, brexanolone is FDA-approved for postpartum depression, and zuranolone showed significant clinical improvements at day 3 and day 42 in MDD and at days 3, 15, 28, and 45 in 196 patients with postpartum depression; zuranolone was subsequently FDA-approved for postpartum depression.

Methods

  • Narrative review of clinical studies up to September 2023 of investigational compounds targeting glutamatergic and/or GABAergic systems as their primary antidepressant mechanism, including compounds with evidence of antidepressant efficacy in at least one successful clinical trial.
  • Evidence levels for antidepressant efficacy are summarized in Tables 1–3; psychedelics ayahuasca and psilocybin are mentioned but not formally included because their direct glutamate/GABA modulation in relation to antidepressant efficacy is unclear.
  • The paper does not report a systematic search strategy, databases, inclusion/exclusion criteria, or quantitative synthesis; this is evident from the Methods section.

Limitations

  • Stated: no clear consensus definition of TRD, with only 17% of studies using the modal two-adequate-trial definition.
  • Stated across trials: inability to effectively blind subjects and raters to ketamine/esketamine, homogenous samples, short durations, limited real-world feasibility, high dropout in some esketamine trials, and safety concerns including suicidality and REMS restrictions for esketamine and brexanolone.
  • Evident from the text: as a narrative review, it lacks a systematic search and meta-analytic synthesis; many compounds have small samples, short durations, and virtually identical designs, requiring larger and longer randomized controlled trials.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/ph16111572

Cites

177 of 177 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

36 Valid · 8 Not valid · 132 Not checked · 20 Own results and interpretations

79 more claims · 21 with their cited sources checked

Create a free account to see all 196 claims and to verify the 197 references still open.

See all claims — free account
  • It may state two separate claims as one. 100
  • Probably not a substantial claim. 25
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 5

Citations

Cites

Research works printed but not linked: 2

  1. Sage Therapeutics (2023, September 04). Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder. Available online: https://www.businesswire.com/news/home/20191205005375/en/4676027/Sage-Therapeutics-Reports-Topline-Results-from-Pivotal-Phase-3-MOUNTAIN-Study-of-SAGE-217-in-Major-Depressive-Disorder.
  2. Sage Therapeutics (2023, September 04). Business Wire. Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression. Available online: https://www.businesswire.com/news/home/20230205005025/en/.

Cited by

See all 48

Metadata

Authors
Vecera, C. M., C. Courtes, A., Jones, G., Soares, J. C., & Machado-Vieira, R.
Affiliations
  • The University of Texas Health Science Center at Houston (US)
  • Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center, Houston, TX 77054, USA
  • John S. Dunn Behavioral Sciences Center at UTHealth Houston, 5615 H.Mark Crosswell Jr St, Houston, TX 77021, USA
Venue
Pharmaceuticals
Publisher
MDPI AG
Published
2023-11-07
Volume
16
Issue
11
Pages
1572
ISSN
1424-8247 (ISSN-L)
OpenAlex
W4388453068
Cited by
48
References
179
Citations by year
2026: 16 · 2025: 20 · 2024: 12
FWCI
1.73
Type
journal article
Language
en
Open access
Locations
  • Pharmaceuticals (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Commons-TMC (Texas Medical Center) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
Keywords
treatment-resistant depression, major depressive disorder, NMDA receptor antagonism, ketamine, esketamine, D-cycloserine, GABA-A receptor modulation, brexanolone, postpartum depression, antidepressant mechanism, drug safety profile

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.